Monte Rosa Therapeutics, Inc. (GLUE)
Company Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.
The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.
Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 24, 2021 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 95 |
Contact Details
Address:
645 Summer Street Boston, MA 02210 United States | |
| Phone | 617 949 2643 |
| Website | monterosatx.com |
Stock Details
| Ticker Symbol | GLUE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $19.00 |
| CIK Code | 1826457 |
| ISIN Number | US61225M1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Markus Warmuth M.D. | President, Chief Executive Officer and Director |
| Dr. Owen B. Wallace Ph.D. | Chief Scientific Officer |
| Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer |
| Ajim A. Tamboli C.F.A. | Chief Financial Officer |
| Jennifer Champoux | Senior Vice President of Operations |
| Dr. Sharon Townson Ph.D. | Chief Technology Officer |
| Phil Nickson J.D., Ph.D. | General Counsel |
| Dr. John C. Castle Ph.D. | Chief Data Scientist |
| Dr. Jullian G. Jones J.D., M.B.A., Ph.D. | Chief Business Officer |
| Dr. Silvia Buonamici Ph.D. | Senior Vice President of Drug Discovery Biology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2022 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 15, 2022 | 8-K | Current report |
| Jun 8, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 11, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 11, 2022 | 8-K | Current report |